{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:35:29Z","timestamp":1792805729030,"version":"4.5.0"},"reference-count":125,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology - Research and Practice"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.prp.2024.155607","type":"journal-article","created":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T06:41:02Z","timestamp":1727246462000},"page":"155607","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["A review on tyrosine kinase inhibitors for targeted breast cancer therapy"],"prefix":"10.1016","volume":"263","author":[{"given":"Vidya","family":"Sankarapandian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramya Lakshmi","family":"Rajendran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Conrad Ondieki","family":"Miruka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Poornima","family":"Sivamani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balu Alagar Venmathi","family":"Maran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajapandiyan","family":"Krishnamoorthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prakash","family":"Gangadaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byeong-Cheol","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.prp.2024.155607_bib1","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1186\/s13045-021-01213-z","article-title":"Global, Regional, and National Cancer Incidence and Death for 29 Cancer Groups in 2019 and Trends Analysis of the Global Cancer Burden, 1990-2019","volume":"14","author":"Lin","year":"2021","journal-title":"J. Hematol. Oncol."},{"issue":"3","key":"10.1016\/j.prp.2024.155607_bib2","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA: A Cancer J. Clin."},{"issue":"1130","key":"10.1016\/j.prp.2024.155607_bib3","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20211033","article-title":"Understanding Breast Cancer as a Global Health Concern","volume":"95","author":"Wilkinson","year":"2022","journal-title":"Br. J. Radio."},{"issue":"2","key":"10.1016\/j.prp.2024.155607_bib4","doi-asserted-by":"crossref","first-page":"109","DOI":"10.4103\/2231-4040.72251","article-title":"Various types and management of breast cancer: an overview","volume":"1","author":"Sharma","year":"2010","journal-title":"J. Adv. Pharm. Technol. Res"},{"issue":"3","key":"10.1016\/j.prp.2024.155607_bib5","doi-asserted-by":"crossref","first-page":"412","DOI":"10.5306\/wjco.v5.i3.412","article-title":"Biological subtypes of breast cancer: prognostic and therapeutic implications","volume":"5","author":"Yersal","year":"2014","journal-title":"World J. Clin. Oncol."},{"key":"10.1016\/j.prp.2024.155607_bib6","article-title":"Ductal carcinoma in situ of the breast","volume":"2012","author":"Lee","year":"2012","journal-title":"Int J. Surg. Oncol."},{"key":"10.1016\/j.prp.2024.155607_bib7","doi-asserted-by":"crossref","first-page":"23","DOI":"10.4137\/CPath.S31563","article-title":"Diversity of breast carcinoma: histological subtypes and clinical relevance","volume":"8","author":"Makki","year":"2015","journal-title":"Clin. Med Insights Pathol."},{"issue":"2","key":"10.1016\/j.prp.2024.155607_bib8","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.gendis.2018.05.001","article-title":"Breast cancer development and progression: risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis","volume":"5","author":"Feng","year":"2018","journal-title":"Genes Dis."},{"key":"10.1016\/j.prp.2024.155607_bib9","doi-asserted-by":"crossref","first-page":"431","DOI":"10.2147\/IJWH.S178349","article-title":"Triple-negative breast cancer: current perspective on the evolving therapeutic landscape","volume":"11","author":"Mehanna","year":"2019","journal-title":"Int J. Women\u2019s. Health"},{"issue":"2","key":"10.1016\/j.prp.2024.155607_bib10","first-page":"162","article-title":"ER\u03b1-negative and triple negative breast cancer: molecular features and potential therapeutic approaches","volume":"1796","author":"Chen","year":"2009","journal-title":"Biochim Biophys. Acta"},{"issue":"2","key":"10.1016\/j.prp.2024.155607_bib11","doi-asserted-by":"crossref","first-page":"37","DOI":"10.29245\/2572-9411\/2018\/2.1150","article-title":"Inflammatory breast cancer: a panoramic overview","volume":"3","author":"van Golen","year":"2018","journal-title":"J. Rare Dis. Res Treat."},{"key":"10.1016\/j.prp.2024.155607_bib12","doi-asserted-by":"crossref","first-page":"321","DOI":"10.2147\/DDDT.S137783","article-title":"Abemaciclib: a CDK4\/6 Inhibitor for the Treatment of HR+\/HER2\u2212 advanced breast cancer","volume":"12","author":"Corona","year":"2018","journal-title":"Drug Des. Devel Ther."},{"issue":"3","key":"10.1016\/j.prp.2024.155607_bib13","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s11523-021-00796-4","article-title":"An overview of PARP inhibitors for the treatment of breast cancer","volume":"16","author":"Cortesi","year":"2021","journal-title":"Target Oncol."},{"key":"10.1016\/j.prp.2024.155607_bib14","doi-asserted-by":"crossref","first-page":"5177","DOI":"10.2147\/OTT.S184971","article-title":"Evidence to date: talazoparib in the treatment of breast cancer","volume":"12","author":"Exman","year":"2019","journal-title":"OncoTargets Ther."},{"issue":"3","key":"10.1016\/j.prp.2024.155607_bib15","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.annonc.2021.11.018","article-title":"Veliparib monotherapy following carboplatin\/paclitaxel plus veliparib combination therapy in patients with germline BRCA-Associated Advanced Breast Cancer: Results of Exploratory Analyses from the Phase III BROCADE3 Trial","volume":"33","author":"Han","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.prp.2024.155607_bib16","doi-asserted-by":"crossref","first-page":"v1","DOI":"10.1093\/annonc\/mdu438.6","article-title":"Breast cancer treatment with everolimus and exemestane for Er+ women - results of the 2Nd interim analysis of the non-interventional trial brawo","volume":"25","author":"Fasching","year":"2014","journal-title":"Ann. Oncol."},{"issue":"7","key":"10.1016\/j.prp.2024.155607_bib17","first-page":"768","article-title":"Alpelisib: a novel therapy for patients with PIK3CA-mutated metastatic breast cancer","volume":"11","author":"Wilhoit","year":"2020","journal-title":"J. Adv. Pr. Oncol."},{"issue":"1","key":"10.1016\/j.prp.2024.155607_bib18","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1158\/1078-0432.CCR-14-0947","article-title":"First-in-human phase I Study of Pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-Kinase (PI3K) inhibitor, in patients with advanced solid tumors","volume":"21","author":"Sarker","year":"2015","journal-title":"Clin. Cancer Res"},{"issue":"10","key":"10.1016\/j.prp.2024.155607_bib19","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.2217\/fon.15.56","article-title":"Buparlisib in Breast Cancer","volume":"11","author":"Sirohi","year":"2015","journal-title":"Future Oncol."},{"issue":"21","key":"10.1016\/j.prp.2024.155607_bib20","doi-asserted-by":"crossref","first-page":"11659","DOI":"10.3390\/ijms222111659","article-title":"Emerging importance of tyrosine kinase inhibitors against cancer: Quo vadis to cure?","volume":"22","author":"Mongre","year":"2021","journal-title":"Int J. Mol. Sci."},{"issue":"43","key":"10.1016\/j.prp.2024.155607_bib21","doi-asserted-by":"crossref","first-page":"75712","DOI":"10.18632\/oncotarget.20095","article-title":"EGFR TKI as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer","volume":"8","author":"Nan","year":"2017","journal-title":"Oncotarget"},{"issue":"10","key":"10.1016\/j.prp.2024.155607_bib22","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1007\/s00018-008-7440-8","article-title":"The epidermal growth factor receptor family: biology driving targeted therapeutics","volume":"65","author":"Wieduwilt","year":"2008","journal-title":"Cell Mol. Life Sci."},{"issue":"1","key":"10.1016\/j.prp.2024.155607_bib23","first-page":"48","article-title":"Epidermal growth factor receptor (EGFR) in lung cancer: an overview and update","volume":"2","author":"Bethune","year":"2010","journal-title":"J. Thorac. Dis."},{"issue":"11","key":"10.1016\/j.prp.2024.155607_bib24","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.3390\/cancers13112748","article-title":"EGFR in Cancer: signaling mechanisms, drugs, and acquired resistance","volume":"13","author":"Uribe","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"5","key":"10.1016\/j.prp.2024.155607_bib25","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1006\/cbir.1995.1086","article-title":"The epidermal growth factor","volume":"19","author":"Boonstra","year":"1995","journal-title":"Cell Biol. Int"},{"issue":"2","key":"10.1016\/j.prp.2024.155607_bib26","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3390\/cells6020013","article-title":"Activation of the EGF receptor by ligand binding and oncogenic mutations: the \u201cRotation Model\u201d","volume":"6","author":"Purba","year":"2017","journal-title":"Cells"},{"issue":"23","key":"10.1016\/j.prp.2024.155607_bib27","doi-asserted-by":"crossref","first-page":"6793","DOI":"10.1093\/emboj\/20.23.6793","article-title":"Tyrosine Phosphorylation of Grb2 by Bcr\/Abl and epidermal growth factor receptor: a novel regulatory mechanism for tyrosine kinase signaling","volume":"20","author":"Li","year":"2001","journal-title":"EMBO J."},{"issue":"6192","key":"10.1016\/j.prp.2024.155607_bib28","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1126\/science.1250373","article-title":"Ras activation by SOS: allosteric regulation by altered fluctuation dynamics","volume":"345","author":"Iversen","year":"2014","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.prp.2024.155607_bib29","doi-asserted-by":"crossref","first-page":"3045","DOI":"10.3892\/ol.2016.5110","article-title":"The Ras\/Raf\/MEK\/ERK signaling pathway and its role in the occurrence and development of HCC","volume":"12","author":"Li","year":"2016","journal-title":"Oncol. Lett."},{"issue":"5","key":"10.1016\/j.prp.2024.155607_bib30","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3390\/cancers9050052","article-title":"Epidermal growth factor receptor cell proliferation signaling pathways","volume":"9","author":"Wee","year":"2017","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.prp.2024.155607_bib31","doi-asserted-by":"crossref","first-page":"5","DOI":"10.5732\/cjc.010.10542","article-title":"Therapeutic targeting of epidermal growth factor receptor in human cancer: successes and limitations","volume":"30","author":"Wykosky","year":"2011","journal-title":"Chin. J. Cancer"},{"issue":"1","key":"10.1016\/j.prp.2024.155607_bib32","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1021\/cb500870a","article-title":"Targeting conformational plasticity of protein kinases","volume":"10","author":"Tong","year":"2015","journal-title":"ACS Chem. Biol."},{"issue":"1","key":"10.1016\/j.prp.2024.155607_bib33","doi-asserted-by":"crossref","first-page":"a001115","DOI":"10.1101\/mcs.a001115","article-title":"ALK: a tyrosine kinase target for cancer therapy","volume":"3","author":"Holla","year":"2017","journal-title":"Cold Spring Harb. Mol. Case Stud."},{"issue":"3","key":"10.1016\/j.prp.2024.155607_bib34","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1586\/14737140.9.3.331","article-title":"Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy","volume":"9","author":"Webb","year":"2009","journal-title":"Expert Rev. Anticancer Ther."},{"issue":"13","key":"10.1016\/j.prp.2024.155607_bib35","doi-asserted-by":"crossref","first-page":"4275","DOI":"10.1158\/1078-0432.CCR-08-0168","article-title":"J\u00e4nne, P. A. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer","volume":"14","author":"Koivunen","year":"2008","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.prp.2024.155607_bib36","doi-asserted-by":"crossref","first-page":"4869","DOI":"10.2147\/OTT.S148604","article-title":"Crizotinib, a MET inhibitor, inhibits growth, migration, and invasion of breast cancer cells in vitro and synergizes with chemotherapeutic agents","volume":"10","author":"Ayoub","year":"2017","journal-title":"Onco Targets Ther."},{"issue":"4","key":"10.1016\/j.prp.2024.155607_bib37","first-page":"267","article-title":"Crizotinib: a breakthrough for targeted therapies in lung cancer","volume":"3","author":"Kwon","year":"2012","journal-title":"J. Adv. Pr. Oncol."},{"issue":"4","key":"10.1016\/j.prp.2024.155607_bib38","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1097\/CAD.0000000000001272","article-title":"Dramatic response to crizotinib in a breast cancer patient with ALK gene rearrangement","volume":"33","author":"Kus","year":"2022","journal-title":"Anti-Cancer Drugs"},{"key":"10.1016\/j.prp.2024.155607_bib39","doi-asserted-by":"crossref","first-page":"4869","DOI":"10.2147\/OTT.S148604","article-title":"Crizotinib, a MET inhibitor, inhibits growth, migration, and invasion of breast cancer cells in vitro and synergizes with chemotherapeutic agents","volume":"10","author":"Ayoub","year":"2017","journal-title":"Onco Targets Ther."},{"issue":"2","key":"10.1016\/j.prp.2024.155607_bib40","first-page":"156","article-title":"Ceritinib for ALK-rearrangement\u2013positive non\u2013small cell lung cancer","volume":"6","author":"Nix","year":"2015","journal-title":"J. Adv. Pr. Oncol."},{"issue":"5","key":"10.1016\/j.prp.2024.155607_bib41","doi-asserted-by":"crossref","DOI":"10.1200\/PO.21.00142","article-title":"STRN-ALK fusion-positive case of breast cancer with response to alectinib","author":"Kelly","year":"2021","journal-title":"JCO Precis Oncol."},{"issue":"3","key":"10.1016\/j.prp.2024.155607_bib42","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1080\/17512433.2019.1570846","article-title":"Lorlatinib for the treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer","volume":"12","author":"Yang","year":"2019","journal-title":"Expert Rev. Clin. Pharm."},{"key":"10.1016\/j.prp.2024.155607_bib43","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/bs.ctdb.2016.10.001","article-title":"VEGF receptor tyrosine kinases: key regulators of vascular function","volume":"123","author":"\u00c1lvarez-Aznar","year":"2017","journal-title":"Curr. Top. Dev. Biol."},{"issue":"12","key":"10.1016\/j.prp.2024.155607_bib44","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1177\/1947601911423031","article-title":"Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis: a crucial target for anti- and pro-angiogenic therapies","volume":"2","author":"Shibuya","year":"2011","journal-title":"Genes Cancer"},{"issue":"3","key":"10.1016\/j.prp.2024.155607_bib45","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1007\/s12565-017-0424-8","article-title":"Vascular endothelial growth factor receptor 1 (VEGFR1) tyrosine kinase signaling facilitates granulation tissue formation with recruitment of VEGFR1+ cells from bone marrow","volume":"93","author":"Park","year":"2018","journal-title":"Anat. Sci. Int"},{"issue":"3","key":"10.1016\/j.prp.2024.155607_bib46","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.cardiores.2004.12.002","article-title":"The biology of vascular endothelial growth factors","volume":"65","author":"Tammela","year":"2005","journal-title":"Cardiovasc Res"},{"issue":"12","key":"10.1016\/j.prp.2024.155607_bib47","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1177\/1947601911423031","article-title":"Vascular Endothelial Growth Factor (VEGF) and Its Receptor (VEGFR) signaling in angiogenesis: a crucial target for anti- and pro-angiogenic therapies","volume":"2","author":"Shibuya","year":"2011","journal-title":"Genes Cancer"},{"key":"10.1016\/j.prp.2024.155607_bib48","doi-asserted-by":"crossref","DOI":"10.1038\/srep39460","article-title":"The angiogenic secretome in VEGF overexpressing breast cancer xenografts","volume":"6","author":"Dore-Savard","year":"2016","journal-title":"Sci. Rep."},{"issue":"7","key":"10.1016\/j.prp.2024.155607_bib49","doi-asserted-by":"crossref","first-page":"a006502","DOI":"10.1101\/cshperspect.a006502","article-title":"Signal transduction by vascular endothelial growth factor receptors","volume":"2","author":"Koch","year":"2012","journal-title":"Cold Spring Harb. Perspect. Med"},{"issue":"4","key":"10.1016\/j.prp.2024.155607_bib50","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/imm.12510","article-title":"in the Immune system: from signalling to chromatin regulation","volume":"146","author":"Lim","year":"2015","journal-title":"Immunology"},{"issue":"1","key":"10.1016\/j.prp.2024.155607_bib51","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1136\/gut.52.1.144","article-title":"Mitogen Activated Protein (MAP) kinase signal transduction pathways and novel anti-inflammatory targets","volume":"52","author":"Hommes","year":"2003","journal-title":"Gut"},{"issue":"4","key":"10.1016\/j.prp.2024.155607_bib52","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s12079-016-0352-8","article-title":"VEGF-A\/VEGFR2 signaling network in endothelial cells relevant to angiogenesis","volume":"10","author":"Abhinand","year":"2016","journal-title":"J. Cell Commun. Signal."},{"issue":"1","key":"10.1016\/j.prp.2024.155607_bib53","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/0046-8177(95)90119-1","article-title":"Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer","volume":"26","author":"Brown","year":"1995","journal-title":"Hum. Pathol."},{"issue":"1","key":"10.1016\/j.prp.2024.155607_bib54","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13045-022-01310-7","article-title":"Recent progress on vascular endothelial growth factor receptor inhibitors with dual targeting capabilities for tumor therapy","volume":"15","author":"Liu","year":"2022","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.prp.2024.155607_bib55","first-page":"108","article-title":"Vascular endothelial growth factor receptor-2 in breast cancer","volume":"1806","author":"Guo","year":"2010","journal-title":"Biochim Biophys. Acta"},{"issue":"8","key":"10.1016\/j.prp.2024.155607_bib56","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.2174\/138945010791591395","article-title":"Vascular endothelial growth factor as an anti-angiogenic target for cancer therapy","volume":"11","author":"Niu","year":"2010","journal-title":"Curr. Drug Targets"},{"issue":"8","key":"10.1016\/j.prp.2024.155607_bib57","doi-asserted-by":"crossref","first-page":"4408","DOI":"10.3390\/ijms23084408","article-title":"Synergistic anti-angiogenic effect of combined VEGFR kinase inhibitors, lenvatinib, and regorafenib: a therapeutic potential for breast cancer","volume":"23","author":"Bajbouj","year":"2022","journal-title":"Int J. Mol. Sci."},{"issue":"10","key":"10.1016\/j.prp.2024.155607_bib58","doi-asserted-by":"crossref","first-page":"a006577","DOI":"10.1101\/cshperspect.a006577","article-title":"Anti-VEGF therapies in the clinic","volume":"2","author":"Meadows","year":"2012","journal-title":"Cold Spring Harb. Perspect. Med"},{"issue":"2","key":"10.1016\/j.prp.2024.155607_bib59","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1517\/13543784.2012.652304","article-title":"Pazopanib for the treatment of breast cancer","volume":"21","author":"Amiri-Kordestani","year":"2012","journal-title":"Expert Opin. Invest. Drugs"},{"issue":"3","key":"10.1016\/j.prp.2024.155607_bib60","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.beem.2017.04.013","article-title":"The molecular basis for RET tyrosine-kinase inhibitors in thyroid cancer","volume":"31","author":"De Falco","year":"2017","journal-title":"Best. Pract. Res. Clin. Endocrinol. Metab."},{"issue":"1","key":"10.1016\/j.prp.2024.155607_bib61","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13045-021-01063-9","article-title":"Therapeutic strategies in RET gene rearranged non-small cell lung cancer","volume":"14","author":"Drusbosky","year":"2021","journal-title":"J. Hematol. Oncol."},{"issue":"8","key":"10.1016\/j.prp.2024.155607_bib62","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1080\/07853890701646256","article-title":"Neurotrophic factor receptor RET: structure, cell biology, and inherited diseases","volume":"39","author":"Runeberg-Roos","year":"2007","journal-title":"Ann. Med."},{"key":"10.1016\/j.prp.2024.155607_bib63","doi-asserted-by":"crossref","unstructured":"Roles of the RET Proto-Oncogene in Cancer and Development. JMA J 2020, 3 (3), 175\u2013181. https:\/\/doi.org\/10.31662\/jmaj.2020-0021.","DOI":"10.31662\/jmaj.2020-0021"},{"issue":"3","key":"10.1016\/j.prp.2024.155607_bib64","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.molmed.2010.12.007","article-title":"RET in breast cancer: functional and therapeutic implications","volume":"17","author":"Morandi","year":"2011","journal-title":"Trends Mol. Med."},{"issue":"2","key":"10.1016\/j.prp.2024.155607_bib65","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1021\/ci6004383","article-title":"Construction and Validation of a RET TK catalytic domain by homology modeling","volume":"47","author":"Tuccinardi","year":"2007","journal-title":"J. Chem. Inf. Model."},{"issue":"1","key":"10.1016\/j.prp.2024.155607_bib66","doi-asserted-by":"crossref","first-page":"4821","DOI":"10.1038\/s41467-018-07341-4","article-title":"RET rearrangements are actionable alterations in breast cancer","volume":"9","author":"Paratala","year":"2018","journal-title":"Nat. Commun."},{"issue":"35","key":"10.1016\/j.prp.2024.155607_bib67","doi-asserted-by":"crossref","first-page":"4352","DOI":"10.1200\/JCO.2012.44.1477","article-title":"RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer","volume":"30","author":"Wang","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.prp.2024.155607_bib68","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1038\/cr.2012.27","article-title":"Identification of RET gene fusion by exon array analyses in \u201cpan-negative\u201d lung cancer from never smokers","volume":"22","author":"Li","year":"2012","journal-title":"Cell Res"},{"issue":"1","key":"10.1016\/j.prp.2024.155607_bib69","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s12885-018-5262-0","article-title":"Expression of RET is associated with oestrogen receptor expression but lacks prognostic significance in breast cancer","volume":"19","author":"Mechera","year":"2019","journal-title":"BMC Cancer"},{"issue":"24","key":"10.1016\/j.prp.2024.155607_bib70","doi-asserted-by":"crossref","first-page":"11732","DOI":"10.1158\/0008-5472.CAN-07-2343","article-title":"A role for glial cell derived neurotrophic factor induced expression by inflammatory cytokines and RET\/GFR Alpha 1 receptor up-regulation in breast cancer","volume":"67","author":"Esseghir","year":"2007","journal-title":"Cancer Res"},{"issue":"9","key":"10.1016\/j.prp.2024.155607_bib71","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1002\/emmm.201302625","article-title":"Ret Inhibition decreases growth and metastatic potential of estrogen receptor positive breast cancer cells","volume":"5","author":"Gattelli","year":"2013","journal-title":"EMBO Mol. Med"},{"issue":"9","key":"10.1016\/j.prp.2024.155607_bib72","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/nrclinonc.2013.124","article-title":"Luminal breast cancer: from biology to treatment","volume":"10","author":"Ignatiadis","year":"2013","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.prp.2024.155607_bib73","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/S0092-8674(00)81717-1","article-title":"The structural basis of estrogen receptor\/coactivator recognition and the antagonism of this interaction by tamoxifen","volume":"95","author":"Shiau","year":"1998","journal-title":"Cell"},{"key":"10.1016\/j.prp.2024.155607_bib74","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.mce.2015.09.035","article-title":"Endocrine resistance in breast cancer \u2013 an overview and update","volume":"418","author":"Clarke","year":"2015","journal-title":"Mol. Cell. Endocrinol."},{"issue":"33","key":"10.1016\/j.prp.2024.155607_bib75","doi-asserted-by":"crossref","first-page":"4648","DOI":"10.1038\/onc.2010.209","article-title":"Targeting the receptor tyrosine kinase RET sensitizes breast cancer cells to tamoxifen treatment and reveals a role for RET in endocrine resistance","volume":"29","author":"Plaza-Menacho","year":"2010","journal-title":"Oncogene"},{"issue":"12","key":"10.1016\/j.prp.2024.155607_bib76","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1007\/s10495-013-0886-7","article-title":"Functional roles of fibroblast growth factor receptors (FGFRs) signaling in human cancers","volume":"18","author":"Tiong","year":"2013","journal-title":"Apoptosis"},{"issue":"6","key":"10.1016\/j.prp.2024.155607_bib77","doi-asserted-by":"crossref","first-page":"614","DOI":"10.3390\/cells8060614","article-title":"Fibroblast growth factor receptors (FGFRs): structures and small molecule inhibitors","volume":"8","author":"Dai","year":"2019","journal-title":"Cells"},{"issue":"10","key":"10.1016\/j.prp.2024.155607_bib78","doi-asserted-by":"crossref","first-page":"3029","DOI":"10.3390\/cancers12103029","article-title":"The FGF\/FGFR system in breast cancer: oncogenic features and therapeutic perspectives","volume":"12","author":"Santolla","year":"2020","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.prp.2024.155607_bib79","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13045-021-01040-2","article-title":"FGFR-TKI resistance in cancer: current status and perspectives","volume":"14","author":"Yue","year":"2021","journal-title":"J. Hematol. Oncol."},{"issue":"6","key":"10.1016\/j.prp.2024.155607_bib80","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.3390\/cancers12061366","article-title":"Erdafitinib resensitizes ABCB1-overexpressing multidrug-resistant cancer cells to cytotoxic anticancer drugs","volume":"12","author":"Wu","year":"2020","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.prp.2024.155607_bib81","first-page":"821","article-title":"Immunohistochemical Expression Of ROS-1 in mammary ductal carcinoma in correlation with hormonal receptor status and Her2Neu expression","volume":"12","author":"Hameedi","year":"2021","journal-title":"Syst. Rev. Pharm."},{"issue":"1","key":"10.1016\/j.prp.2024.155607_bib82","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/s41571-020-0408-9","article-title":"ROS1-dependent cancers - biology, diagnostics and therapeutics","volume":"18","author":"Drilon","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.prp.2024.155607_bib83","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1007\/s40265-019-01164-3","article-title":"Targeting ROS1 rearrangements in non-small cell lung cancer: crizotinib and newer generation tyrosine kinase inhibitors","volume":"79","author":"Morris","year":"2019","journal-title":"Drugs"},{"issue":"2","key":"10.1016\/j.prp.2024.155607_bib84","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1158\/1535-7163.MCT-21-0395","article-title":"Resistance profile and structural modeling of next-generation ROS1 tyrosine kinase inhibitors","volume":"21","author":"Keddy","year":"2022","journal-title":"Mol. Cancer Ther."},{"issue":"22","key":"10.1016\/j.prp.2024.155607_bib85","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.2217\/fon-2022-0358","article-title":"ROSALINE: A Phase II, neoadjuvant study targeting ROS1 in combination with endocrine therapy in invasive lobular carcinoma of the breast","volume":"18","author":"Agostinetto","year":"2022","journal-title":"Future Oncol."},{"issue":"1","key":"10.1016\/j.prp.2024.155607_bib86","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1017\/S0266462319000813","article-title":"U.S. food and drug administration anticancer drug approval trends from 2016 to 2018 for lung, colorectal, breast, and prostate cancer","volume":"36","author":"Ribeiro","year":"2020","journal-title":"Int J. Technol. Assess. Health Care"},{"issue":"10","key":"10.1016\/j.prp.2024.155607_bib87","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1002\/1878-0261.13214","article-title":"Pre- and post-treatment blood-based genomic landscape of patients with ROS1 or NTRK fusion-positive solid tumours treated with entrectinib","volume":"16","author":"Dziadziuszko","year":"2022","journal-title":"Mol. Oncol."},{"issue":"11","key":"10.1016\/j.prp.2024.155607_bib88","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.tig.2019.08.006","article-title":"Toward clinical implementation of next-generation sequencing-based genetic testing in rare diseases: where are we?","volume":"35","author":"Liu","year":"2019","journal-title":"Trends Genet"},{"key":"10.1016\/j.prp.2024.155607_bib89","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.112974","article-title":"Entrectinib, a new multi-target inhibitor for cancer therapy","volume":"150","author":"Jiang","year":"2022","journal-title":"Biomed. Pharm."},{"issue":"4","key":"10.1016\/j.prp.2024.155607_bib90","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1158\/1535-7163.MCT-15-0758","article-title":"Entrectinib, a Pan-TRK, ROS1, and ALK inhibitor with activity in multiple molecularly defined cancer indications","volume":"15","author":"Ardini","year":"2016","journal-title":"Mol. Cancer Ther."},{"issue":"13","key":"10.1016\/j.prp.2024.155607_bib91","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1007\/s40265-019-01177-y","article-title":"Entrectinib: first global approval","volume":"79","author":"Al-Salama","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.prp.2024.155607_bib92","doi-asserted-by":"crossref","first-page":"3549","DOI":"10.2147\/DDDT.S147384","article-title":"Entrectinib and Other ALK\/TRK inhibitors for the treatment of neuroblastoma","volume":"12","author":"Pacenta","year":"2018","journal-title":"Drug Des. Devel Ther."},{"issue":"4","key":"10.1016\/j.prp.2024.155607_bib93","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1309\/YMJ3A83TB39MRUT9","article-title":"Correlation of HER-2 status with estrogen and progesterone receptors and histologic features in 3,655 invasive breast carcinomas","volume":"123","author":"Lal","year":"2005","journal-title":"Am. J. Clin. Pathol."},{"issue":"2","key":"10.1016\/j.prp.2024.155607_bib94","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1093\/jnci\/95.2.142","article-title":"Quantitative association between HER-2\/Neu and steroid hormone receptors in hormone receptor-positive primary breast cancer","volume":"95","author":"Konecny","year":"2003","journal-title":"J. Natl. Cancer Inst."},{"issue":"12","key":"10.1016\/j.prp.2024.155607_bib95","doi-asserted-by":"crossref","first-page":"5321","DOI":"10.1073\/pnas.89.12.5321","article-title":"ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization","volume":"89","author":"Kallioniemi","year":"1992","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"4785","key":"10.1016\/j.prp.2024.155607_bib96","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1126\/science.3798106","article-title":"Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/Neu Oncogene","volume":"235","author":"Slamon","year":"1987","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.prp.2024.155607_bib97","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1111\/j.1365-2559.2006.02403.x","article-title":"HER2 Status in pure ductal carcinoma in situ and in the intraductal and invasive components of invasive ductal carcinoma determined by fluorescence in situ hybridization and immunohistochemistry","volume":"48","author":"Park","year":"2006","journal-title":"Histopathology"},{"issue":"36","key":"10.1016\/j.prp.2024.155607_bib98","doi-asserted-by":"crossref","first-page":"5658","DOI":"10.1200\/JCO.2006.07.0250","article-title":"Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer","volume":"24","author":"Gabos","year":"2006","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.prp.2024.155607_bib99","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.5858\/arpa.2018-0902-SA","article-title":"Human Epidermal Growth Factor Receptor 2 testing in breast cancer: american society of clinical oncology\/college of american pathologists clinical practice guideline focused update","volume":"142","author":"Wolff","year":"2018","journal-title":"Arch. Pathol. Lab Med"},{"issue":"1","key":"10.1016\/j.prp.2024.155607_bib100","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41523-021-00265-1","article-title":"HER2-positive breast cancer and tyrosine kinase inhibitors: the time is now","volume":"7","author":"Schlam","year":"2021","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.prp.2024.155607_bib101","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ctrv.2018.05.004","article-title":"Tyrosine kinase inhibitors for brain metastases in HER2-positive breast cancer","volume":"67","author":"Duchnowska","year":"2018","journal-title":"Cancer Treat. Rev."},{"issue":"8","key":"10.1016\/j.prp.2024.155607_bib102","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1200\/JCO.2009.25.8707","article-title":"Neratinib, an Irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced erbb2-positive breast cancer","volume":"28","author":"Burstein","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.prp.2024.155607_bib103","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/978-3-319-91442-8_2","article-title":"Lapatinib","volume":"211","author":"Voigtlaender","year":"2018","journal-title":"Recent Results Cancer Res"},{"issue":"2","key":"10.1016\/j.prp.2024.155607_bib104","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ctrv.2008.09.003","article-title":"HER2-targeted therapy in breast cancer. monoclonal antibodies and tyrosine kinase inhibitors","volume":"35","author":"Nielsen","year":"2009","journal-title":"Cancer Treat. Rev."},{"issue":"1","key":"10.1016\/j.prp.2024.155607_bib105","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1038\/s41598-022-06677-8","article-title":"Dual targeting micelles loaded with paclitaxel and lapatinib for combinational therapy of brain metastases from breast cancer","volume":"12","author":"Lu","year":"2022","journal-title":"Sci. Rep."},{"issue":"5","key":"10.1016\/j.prp.2024.155607_bib106","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1158\/1535-7163.MCT-21-0847","article-title":"Tucatinib has selective activity in HER2-positive cancers and significant combined activity with approved and novel breast cancer-targeted therapies","volume":"21","author":"O\u2019Brien","year":"2022","journal-title":"Mol. Cancer Ther."},{"issue":"3","key":"10.1016\/j.prp.2024.155607_bib107","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.annonc.2021.12.005","article-title":"Tucatinib versus Placebo Added to Trastuzumab and Capecitabine for Patients with Pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis","volume":"33","author":"Curigliano","year":"2022","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.prp.2024.155607_bib108","first-page":"39","article-title":"The efficacy of tucatinib-based therapeutic approaches for HER2-positive breast cancer","volume":"9","author":"Sirhan","year":"2022","journal-title":"Mil. Med. Res."},{"key":"10.1016\/j.prp.2024.155607_bib109","doi-asserted-by":"crossref","DOI":"10.1016\/j.anndiagpath.2022.152017","article-title":"TRKB acts as a prognostic predictive marker in her-2 positive breast cancer","volume":"60","author":"Zhang","year":"2022","journal-title":"Ann. Diagn. Pathol."},{"issue":"10","key":"10.1016\/j.prp.2024.155607_bib110","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.2174\/0929867329666220801145639","article-title":"Research progress on small molecules inhibitors targeting TRK kinases","volume":"30","author":"Liu","year":"1994","journal-title":"Curr. Med. Chem."},{"issue":"5","key":"10.1016\/j.prp.2024.155607_bib111","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1002\/j.1460-2075.1994.tb06361.x","article-title":"Activation of MEK family kinases requires phosphorylation of two conserved Ser\/Thr residues","volume":"13","author":"Zheng","year":"1994","journal-title":"EMBO J."},{"issue":"9","key":"10.1016\/j.prp.2024.155607_bib112","doi-asserted-by":"crossref","first-page":"954","DOI":"10.18632\/oncotarget.652","article-title":"Mutations and deregulation of Ras\/Raf\/MEK\/ERK and PI3K\/PTEN\/Akt\/mTOR cascades which alter therapy response","volume":"3","author":"McCubrey","year":"2012","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.prp.2024.155607_bib113","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s13045-020-0846-y","article-title":"Combination of PI3K and MEK inhibitors yields durable remission in PDX Models of PIK3CA-mutated metaplastic breast cancers","volume":"13","author":"Coussy","year":"2020","journal-title":"J. Hematol. Oncol."},{"issue":"5","key":"10.1016\/j.prp.2024.155607_bib114","doi-asserted-by":"crossref","first-page":"3055","DOI":"10.3892\/or.2017.5955","article-title":"MEK Inhibitor, PD98059, promotes breast cancer cell migration by inducing \u03b2-catenin nuclear accumulation","volume":"38","author":"Zhao","year":"2017","journal-title":"Oncol. Rep."},{"issue":"9","key":"10.1016\/j.prp.2024.155607_bib115","doi-asserted-by":"crossref","first-page":"9269","DOI":"10.1007\/s13277-014-1901-5","article-title":"MEK inhibitor effective against proliferation in breast cancer cell","volume":"35","author":"Zhou","year":"2014","journal-title":"Tumor Biol."},{"issue":"1","key":"10.1016\/j.prp.2024.155607_bib116","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1517\/14728222.2011.645805","article-title":"Targeting the MAPK\u2013RAS\u2013RAF signaling pathway in cancer therapy","volume":"16","author":"Santarpia","year":"2012","journal-title":"Expert Opin. Ther. Targets"},{"issue":"10","key":"10.1016\/j.prp.2024.155607_bib117","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.3390\/molecules22101551","article-title":"Current development status of MEK inhibitors","volume":"22","author":"Cheng","year":"2017","journal-title":"Molecules"},{"key":"10.1016\/j.prp.2024.155607_bib118","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2022.115233","article-title":"A Kinase Inhibitor Screen Reveals MEK1\/2 as a novel therapeutic target to antagonize IGF1R-mediated antiestrogen resistance in er\u03b1-positive luminal breast cancer","volume":"204","author":"Wester","year":"2022","journal-title":"Biochem Pharm."},{"issue":"2","key":"10.1016\/j.prp.2024.155607_bib119","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1002\/ijc.31052","article-title":"The Impact of P-glycoprotein and breast cancer resistance protein on the brain pharmacokinetics and pharmacodynamics of a panel of MEK Inhibitors","volume":"142","author":"de Gooijer","year":"2018","journal-title":"Int J. Cancer"},{"issue":"3","key":"10.1016\/j.prp.2024.155607_bib120","doi-asserted-by":"crossref","first-page":"731","DOI":"10.3390\/cancers12030731","article-title":"Tyrosine kinase inhibitors in cancer: breakthrough and challenges of targeted therapy","volume":"12","author":"Pottier","year":"2020","journal-title":"Cancers"},{"issue":"0)","key":"10.1016\/j.prp.2024.155607_bib121","article-title":"Drug-related toxicity in breast cancer patients: a new path towards tailored treatment?\u2014a narrative review","volume":"5","author":"Lai","year":"2022","journal-title":"Precis. Cancer Med."},{"issue":"5","key":"10.1016\/j.prp.2024.155607_bib122","doi-asserted-by":"crossref","first-page":"470","DOI":"10.2174\/138920009788897975","article-title":"Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects","volume":"10","author":"Hartmann","year":"2009","journal-title":"Curr. Drug Metab."},{"issue":"1","key":"10.1016\/j.prp.2024.155607_bib123","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41392-023-01469-6","article-title":"Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management","volume":"8","author":"Shyam Sunder","year":"2023","journal-title":"Sig Transduct. Target Ther."},{"issue":"26","key":"10.1016\/j.prp.2024.155607_bib124","article-title":"Side effects and medication adherence of tyrosine kinase inhibitors for patients with chronic Myeloid Leukemia in Taiwan","volume":"97","author":"Tsai","year":"2018","journal-title":"Med. (Baltim. )"},{"issue":"2","key":"10.1016\/j.prp.2024.155607_bib125","doi-asserted-by":"crossref","first-page":"114","DOI":"10.3892\/etm.2021.11037","article-title":"Tyrosine kinase inhibitors in breast cancer (Review)","volume":"23","author":"Iancu","year":"2022","journal-title":"Exp. Ther. Med"}],"container-title":["Pathology - Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033824005181?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033824005181?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,23]],"date-time":"2024-11-23T03:52:03Z","timestamp":1732333923000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0344033824005181"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":125,"alternative-id":["S0344033824005181"],"URL":"https:\/\/doi.org\/10.1016\/j.prp.2024.155607","relation":{},"ISSN":["0344-0338"],"issn-type":[{"value":"0344-0338","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A review on tyrosine kinase inhibitors for targeted breast cancer therapy","name":"articletitle","label":"Article Title"},{"value":"Pathology - Research and Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prp.2024.155607","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier GmbH. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"155607"}}